I Survived a Dangerous and Painful Skin Disorder

ANTONIO TORRES, A 24-year-old from Denver, used to spend six hours each day bathing and meticulously wrapping the red, raw ...
The Manila Times

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in ...
Medscape

First Patient With Recessive Dystrophic Epidermolysis Bullosa Treated With New Gene Therapy

The first-of-its kind gene therapy uses a patient’s skin cells to create sheets to treat the open wounds caused by the rare, ...
Managed Healthcare Executive

2025 FDA dermatology approvals: A new gene therapy and two targeted therapies

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...
Stocks Telegraph

Abeona Therapeutics Inc. (ABEO) Jumps 9% in Pre-market: After First Patient Treatment Announcement

Summary • Abeona Therapeutics Inc. shares rose 9% in pre-market trading, reaching $5.32. • The price increase follows the ...
The Manila Times

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN ...
Fierce Pharma

House endorses bill that would revive FDA's rare pediatric review voucher program

The U.S. House of Representatives has given a unanimous thumbs up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December ...
Taiwan News

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity ...